Invitrogen expects to continue its aggressive acquisition strategy through the remainder of the year, but it is possible after a string of relatively small purchases that the firm may be ready to add a "transforming" piece to its business, CEO Greg Lucier suggested during a webcast last week.

Lucier was one of several members of Invitrogen's management to address attendees of the company's 2005 investor meeting at its headquarters in Carlsbad, Calif.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.